Janus Henderson Investors

Funding rounds backed by Janus Henderson Investors.

Export CSV
Funding disclosed in full
$1.6B
Median round
$65M
Rounds in calculation
13
13 rounds
LatestLargest
Funding rounds with company descriptions, amounts, stages and announcement dates
CompanyRoundMarketInvestorsAnnouncedDetails
Epicrispr Biotechnologies

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries CBiotechUnited States
9 participantsabrdnAngelini VenturesCormorant Asset ManagementDuquesne Family OfficeFidelity Management & Research CompanyJanus Henderson InvestorsOctagon CapitalReadout CapitalSanofi Ventures
Draig Therapeutics

Developing transformative, best-in-class neuropsychiatric therapies

$65MSeries BBiotechUnited Kingdom
12 participantsAccess BiotechnologyBritish Business BankCanaan PartnersDeep Track CapitalICGJanus Henderson InvestorsJefferson Life SciencesMarshall WaceSanofi VenturesSchroders CapitalSR OneSV Health Investors
Triveni Bio

Develops novel antibody treatments for immunological and inflammatory disorders

$65MSeries CBiotechUnited States
7 participantsAlexandria VentureAscenta CapitalAtlas VentureDeep Track CapitalFidelityGoldman SachsJanus Henderson Investors
Calyxo

Develops medical devices for kidney stone treatment and removal

$40MSeries FHealthtechUnited States
5 participantsAlly Bridge GroupAvidity PartnersCRGJanus Henderson InvestorsQuesta Capital
Ambrosia Biosciences

Develops orally delivered, small molecule-based therapies for obesity and other metabolic disorders

$100MSeries BBiotechUnited States
7 participantsBlue Owl Healthcare OpportunitiesBoulder VenturesBVF PartnersDeep Track CapitalJanus Henderson InvestorsRedmileSamsara BioCapital
Poplar Therapeutics

Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions

$45MSeries A+BiotechUnited States
5 participantsArrowMark PartnersJanus Henderson InvestorsRA CapitalSR OneVida Ventures
Korsana Biosciences

Develops novel therapies to reduce the burden of neurodegenerative diseases

$175MSeries ABiotechUnited States
8 participantsFairmountForesite CapitalJanus Henderson InvestorsJ.P. Morgan Life Sciences Private CapitalSanofi VenturesTCGXVenrock Healthcare Capital PartnersWellington Management
ILiAD Biotechnologies

Developing a next-generation pertussis vaccine candidate BPZE1

$115MSeries BBiotechUnited States
4 participantsAI Life SciencesBNP Paribas Asset Management AltsJanus Henderson InvestorsRA Capital Management
CesiumAstro

Provides next-generation space and defense communications

$470MSeries CSpace techUnited States
10 participantsAirbus VenturesDevelopment Bank of JapanEDBIExport-Import Bank of the United States (EXIM)Janus Henderson InvestorsJ.P. MorganMESHNewSpace CapitalTrousdale VenturesWoven Capital
TRex Bio

Develops precision immunoregulatory medicines based on tissue Treg biology

$50MUndisclosedBiotechUnited States
11 participantsAffinity Asset AdvisorsAlexandria Venture InvestmentsAvego BioScience CapitalBalyasny Asset ManagementDelos CapitalEli Lilly and CompanyJanus Henderson InvestorsJohnson & Johnson Innovation – JJDCPfizer VenturesPolaris PartnersSV Health Investors
Think Bioscience

Develops small molecule drugs for historically challenging drug targets

$55MSeries ABiotechUnited States
10 participantsAV8 VenturesBuff Gold VenturesCE-VenturesCU InnovationsInnovation EndeavorsJanus Henderson InvestorsMBX CapitalRegeneron VenturesT.A. SpringerYK Bioventures
Caldera Therapeutics

Develops bispecific antibody CLD-423 for inflammatory bowel disease

$37.5MSeries A1BiotechUnited States
5 participantsJanus Henderson InvestorsLAVOmega FundsvenBioWellington Management
Parabilis Medicines

Develops medicines targeting historically undruggable protein targets in cancer

$305MSeries FBiotechUnited States
23 participantsAlderline GroupARCH Venture PartnersCatalio Capital ManagementCormorant Asset ManagementFarallon Capital ManagementFidelity Management & Research CompanyForesite CapitalFrazier Life SciencesGeneral CatalystGV (Google Ventures)HBM HealthcareInvusJanus Henderson InvestorsMarshall WaceMilky Way InvestmentsNextech InvestRA Capital ManagementRock Springs CapitalSamsara BioCapitalSixty Degree CapitalSoleus CapitalT. Rowe Price AssociatesvenBio Partners